Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) is set to announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to analysts' expectations of $26.84 million. During the same quarter in the prior year, the firm earned ($0.76) EPS. On average, analysts expect Esperion Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Esperion Therapeutics Trading Down 1.0 %
ESPR traded down $0.02 during trading on Tuesday, hitting $1.97. The company's stock had a trading volume of 2,335,626 shares, compared to its average volume of 6,609,319. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40. The firm has a market capitalization of $373.12 million, a price-to-earnings ratio of -0.93 and a beta of 0.84. The business's fifty day simple moving average is $2.37 and its 200 day simple moving average is $2.02.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the stock. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, April 10th. Bank of America downgraded Esperion Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, January 3rd. Finally, HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Monday, March 25th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $9.33.
Get Our Latest Stock Report on Esperion Therapeutics
Esperion Therapeutics Company Profile
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
See Also
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
